Three New Hires Enable Huntsville-Based Kailos Genetics To Respond To Growing List Of Pilot Projects Seeking To Evaluate Technology

HUNTSVILLE, AL: Kailos Genetics, a company focused on putting genetics into practice through its proprietary targeted enrichment technology, today announced the expansion of its development team with the addition of three research and development scientists.

Kailos Genetics’ CEO, Brian Pollock, commented: “Interest in our proprietary targeted enrichment technology from outside the company continues to fuel our growth – both in terms of projects, people, and potential strategic partnerships. We are excited for Kailos and those who have approached us seeking to find a better solution for their business in targeted enrichment”. Joining the company are: Katie Jansen Spayd, Ph.D., Senior R&D Scientist, Irina Vasenkova, Ph.D., Principle R&D Scientist, and Tatiana Shvetsova, R&D Scientist.

Troy Moore, Kailos Genetics’ Chief Scientific Officer, added: “Katie, Irina and Tatiana bring the knowledge and experience needed to optimize products in development, while accelerating plans for new applications. As the market for next generation sequencing shifts to the newer platforms, with sequencing times measured in ‘hours’ versus ‘days’, we must realize advancements in targeted enrichment strategies to fully amortize these gains”.

Kailos Genetics licensed a proprietary targeted enrichment technology from Washington University in St. Louis in 2010. This novel method for highly multiplexed targeting of regions of the genome for deep sequencing is the most scalable on the market today, and is simple to implement. It is the first method that couples multiplex PCR with sample-specific DNA barcodes and next-generation sequencing to enable highly multiplex mutation discovery in candidate genes for multiple samples in parallel.

About Kailos Genetics

For more information, visit www.kailosgenetics.com

Forward-Looking Statement

This release and oral statements made with respect to information contained in this release, including statements about the market potential of Kailos Genetics constitute forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. The words “expects,” “potentially,” “anticipates,” “could,” “calls for” and similar expressions also identify forward-looking statements. These statements are based upon management’s current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with our ability to market, commercialize and achieve market acceptancefor Kailos Genetics’ products, or to develop or partner any of our other products.